Project Grant K99HL181285
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $167K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
- This Project Grant award for $686,640, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at Columbia University to advance the understanding of macrophage efferocytosis as a therapeutic target for atherosclerotic cardiovascular disease (ACVD). The project aims to: 1) Determine how the knockout of the candidate gene ILRUN enhances macrophage efferocytosis and mitigates atherosclerosis; and 2)...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, is focused on studying the role of indole metabolites as danger signals in the pathogenesis of acute respiratory distress syndrome (ARDS). The $688,163 award to the University of Pittsburgh covers the period from Sep 1, 2025 to May 31, 2029. The research aims to investigate how microbial-derived indole metabolites activate regulated cell death...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $135,930 to the University of Connecticut Health Center to investigate the role of the TRPM7 ion channel in macrophage signaling and its impact on the development of atherosclerosis. The research aims to generate macrophage-specific TRPM7 deletion mice and subject them to a high-fat, Western diet atherosclerosis model to determine how in vivo TRPM7 deletion...
- This Project Grant award, totaling $786,060.00, was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate how hypertension induces "trained immunity" in myeloid cells, which may drive the development of atherosclerosis even after lowering cholesterol and blood pressure. Key research activities include: Transplanting hematopoietic stem and progenitor cells from hypertensive mice into...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a $771,485 research project titled "CAROTID-MAP CAROTID ATHEROSCLEROTIC RISK ASSESSMENT THROUGH IMAGING ANDPREDICTION". The project aims to develop reliable imaging-derived markers in carotid artery computed tomography angiography (CTA) scans to identify high-risk plaque features associated with cryptogenic stroke. The research...
- The federal Project Grant award for "NUTRIENT SENSING OF APOPTOTIC CELLS BY MACROPHAGES RESOLVES INFLAMMATION, DRIVES ATHEROSCLEROSIS REGRESSION, AND PROMOTES FEATURES OF PLAQUE INSTABILITY" was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $659,441.00. The award supports research to define the mechanisms underlying the successive clearance of apoptotic cells by macrophages, with the goal of revealing new therapeutic...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- The federal Project Grant award titled "REDUCING PLASMA CHOLESTEROL AND ATHEROSCLEROSIS USING MICRORNA-30C ANALOG C2" was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to New York University's Long Island School of Medicine. The $1,364,153 award, granted on September 24, 2025, supports research to investigate the use of a synthetic microRNA-30c analog, C2, to reduce plasma cholesterol levels and atherosclerosis in mice. The...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $790,498 to the University of Southern California (USC) for a research project entitled "Targeting PCBP1 to Ameliorate Pathological Angiogenesis". The grant, which runs from September 1, 2025 to June 30, 2030, aims to investigate the role of the PCBP1 protein and its target AARS2 in regulating vascular endothelial growth factor (VEGF) signaling and...